期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 130, 期 -, 页码 1-12出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2018.06.007
关键词
NSCLC; First line; Immunotherapy; Pembrolizumab; Nivolumab; Avelumab; Atezolizumab; Durvalumab
资金
- Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)
- A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus
- Borsa Dottorati FSE XXXII Ciclo Unime
During the last two decades front-line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) has profoundly changed moving from the old one size fits all concept to a histology-based approach and then, for a small subgroup of patients to a molecularly-selected one. The development of immune checkpoint inhibitors and the unprecedented results reported in 2nd/3rd line prompted the evaluation of these novel therapeutic agents in chemotherapy-naive patients either alone or in combination with platinum-based chemotherapy. Several randomized trials are evaluating the impact of immune-checkpoint inhibitors in 1st line and some of them have yet produced preliminary evidence of efficacy. However, still a long way to go and several questions are still unanswered, including proper patients selection, optimal sequential/combinatorial use of these agents, appropriate treatment duration, and finally the identification of predictive biomarkers. The aim of this paper is to provide a comprehensive overview on the growing role of immune checkpoint inhibitors in the upfront treatment of advanced non-oncogene addicted NSCLC either as single agent or in combination with other agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据